Maxim Group analyst Jason McCarthy maintained a Buy rating on Omeros Corp (NASDAQ: OMER) today and set a price target of $32. The company’s shares closed yesterday at $21.70.
McCarthy noted:
“Omeros reported Omidria revenues, up slightly from $1.58M in Q1. Omeros reported a net loss for the quarter of $33.7M, and a cash balance of $88M.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 13.9% and a 43.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Omeros Corp is a Strong Buy with an average price target of $29, a 33.6% upside from current levels. In a report issued on July 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $34 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.20 and a one-year low of $8.36. Currently, Omeros Corp has an average volume of 787K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
